CN Patent

CN114404618A — 放射性药物水溶液及其用途

Assigned to Beijing Cotimes Biotech Co Ltd · Expires 2022-04-29 · 4y expired

What this patent protects

本申请涉及放射性药物水溶液及其用途，所述放射性药物水溶液包括由放射性金属核素和靶向PSMA的分子形成的络合物（例如，包括放射性核素络合物[ 177 Lu]Lu‑EB‑PSMA）和稳定剂，所述稳定剂优选为龙胆酸、乙醇、甲硫氨酸中的一种或两种以上。

USPTO Abstract

本申请涉及放射性药物水溶液及其用途，所述放射性药物水溶液包括由放射性金属核素和靶向PSMA的分子形成的络合物（例如，包括放射性核素络合物[ 177 Lu]Lu‑EB‑PSMA）和稳定剂，所述稳定剂优选为龙胆酸、乙醇、甲硫氨酸中的一种或两种以上。

Drugs covered by this patent

lutetium-lu-177-dotatate (Lutetium Lu 177 Dotatate) · National Cancer Institute (NCI)

Patent Metadata

Patent number: CN114404618A
Jurisdiction: CN
Classification: —
Expires: 2022-04-29
Drug substance claim: No
Drug product claim: No
Assignee: Beijing Cotimes Biotech Co Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.